Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
DURHAM, NC – AUGUST 20, 2013 – Zenalux Biomedical, Inc., a biomedical diagnostics company, is now collaborating with Roswell Park Cancer Institute through the Zenalux Research Partnership program. The partnership has been formed to enable Roswell to use the Zenascope™ PC1 for interstitial photodynamic therapy. The PC1 will be used to monitor blood concentration, oxygen saturation, and drug concentration during surgical procedures.
“The excellent technical support, ease-of-use, and speed of the real-time spectroscopy system makes it ideal for clinical use,” said Gal Shafirstein, Professor of Oncology, Departments of Cell Stress Biology and Head and Neck Surgery at Roswell Park Cancer Institute. “The Zenascope’s real time monitoring of critical biological endpoints may be a key enabler in translating our PDT technology into widespread clinical use.”
The first step in the research collaboration will be to demonstrate the ability to carry out real-time measurement of drug concentration in addition to blood concentration and oxygen saturation. The ability to quickly customize the Zenascope PC1 to include the measurement of drug concentration is just one example of how the Zenalux system can be easily customized to measure biomarkers of choice.
“We are very excited to expand our Research Partnership program to include the Roswell Park Cancer Institute,” said Jesko von Windheim, CEO of Zenalux. “It’s an honor to be working with another leader in the medical field. We expect that the success of our current work will lead to further collaborations with the Institute in the future.”
Help employers find you! Check out all the jobs and post your resume.
